DUPILUMAB, Upadacitinib, Upadacitinib
M24-601
Approved small_molecule active
Quick answer
DUPILUMAB, Upadacitinib, Upadacitinib for Atopic Dermatitis is a Approved program (small_molecule) at AbbVie Deutschland GmbH & Co. KG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AbbVie Deutschland GmbH & Co. KG
- Indication
- Atopic Dermatitis
- Phase
- Approved
- Modality
- small_molecule
- Status
- active